Protein Thermodynamic Destabilization in the Assessment of Pathogenicity of a Variant of Uncertain Significance in Cardiac Myosin Binding Protein C.


Journal

Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585

Informations de publication

Date de publication:
10 2020
Historique:
received: 18 10 2019
accepted: 20 01 2020
pubmed: 9 2 2020
medline: 15 12 2020
entrez: 9 2 2020
Statut: ppublish

Résumé

In the era of next generation sequencing (NGS), genetic testing for inherited disorders identifies an ever-increasing number of variants whose pathogenicity remains unclear. These variants of uncertain significance (VUS) limit the reach of genetic testing in clinical practice. The VUS for hypertrophic cardiomyopathy (HCM), the most common familial heart disease, constitute over 60% of entries for missense variants shown in ClinVar database. We have studied a novel VUS (c.1809T>G-p.I603M) in the most frequently mutated gene in HCM, MYBPC3, which codes for cardiac myosin-binding protein C (cMyBPC). Our determinations of pathogenicity integrate bioinformatics evaluation and functional studies of RNA splicing and protein thermodynamic stability. In silico prediction and mRNA analysis indicated no alteration of RNA splicing induced by the variant. At the protein level, the p.I603M mutation maps to the C4 domain of cMyBPC. Although the mutation does not perturb much the overall structure of the C4 domain, the stability of C4 I603M is severely compromised as detected by circular dichroism and differential scanning calorimetry experiments. Taking into account the highly destabilizing effect of the mutation in the structure of C4, we propose reclassification of variant p.I603M as likely pathogenic. Looking into the future, the workflow described here can be used to refine the assignment of pathogenicity of variants of uncertain significance in MYBPC3.

Identifiants

pubmed: 32034629
doi: 10.1007/s12265-020-09959-6
pii: 10.1007/s12265-020-09959-6
doi:

Substances chimiques

Carrier Proteins 0
myosin-binding protein C 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

867-877

Auteurs

Maria Rosaria Pricolo (MR)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. mrpricolo@cnic.es.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy. mrpricolo@cnic.es.

Elías Herrero-Galán (E)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.

Cristina Mazzaccara (C)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate s.c. a r.l., Naples, Italy.

Maria Angela Losi (MA)

Dipartimento di Scienze Biomediche Avanzate, Università Federico II, Naples, Italy.

Jorge Alegre-Cebollada (J)

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. jalegre@cnic.es.

Giulia Frisso (G)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate s.c. a r.l., Naples, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH